Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Clsd save search
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published: 2024-01-16 (Crawled : 20:00) - prnewswire.com
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.49%
H: 3.17%
C: 1.94%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.94%
rgx-314 aaviate positive treatment trial
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2023-11-03 (Crawled : 23:00) - prnewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
| Email alert
Add to watchlist
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
| Email alert
Add to watchlist
rgx-314 altitude year one positive treatment trial diabetic
Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
Published: 2023-10-16 (Crawled : 11:00) - globenewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 2.44%
H: 4.31%
C: 1.44%
positive retina meeting extension study
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
Published: 2023-02-21 (Crawled : 12:20) - globenewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 2.9%
H: 0.0%
C: -3.52%
microinjector cls-ax trial positive
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
Published: 2023-02-02 (Crawled : 12:20) - globenewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 9.09%
H: 10.12%
C: -11.31%
cls-ax extension positive results study
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
Published: 2022-11-09 (Crawled : 12:00) - globenewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: -7.14%
H: 21.54%
C: -1.54%
cls-ax trial positive results
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-11-03 (Crawled : 12:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -3.01%
H: 0.77%
C: -10.46%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.74%
H: 11.76%
C: 7.35%
rgx-314 altitude treatment expansion trial positive diabetic
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
Published: 2022-10-04 (Crawled : 13:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.66%
H: 8.18%
C: -7.11%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 1.67%
H: 15.57%
C: 12.3%
space meeting positive platform
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD
Published: 2022-10-03 (Crawled : 13:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 2.16%
H: 0.3%
C: -10.48%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.88%
H: 5.26%
C: 5.26%
rgx-314 treatment trials positive
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2022-02-12 (Crawled : 20:20) - prnewswire.com
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
| Email alert
Add to watchlist
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
| Email alert
Add to watchlist
rgx-314 treatment liver trial positive diabetic diabetes
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-12-21 (Crawled : 13:00) - biospace.com/
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: -1.03%
H: 4.18%
C: 0.7%
treatment axitinib trial cls-ax phase 1 positive results
REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021
Published: 2021-11-12 (Crawled : 22:00) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 0.41%
H: 1.43%
C: -0.41%
positive trials liver trial diabetic diabetes
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting
Published: 2021-10-09 (Crawled : 16:20) - prnewswire.com
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
| Email alert
Add to watchlist
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
| Email alert
Add to watchlist
treatment positive retina liver trial diabetic diabetes
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Published: 2021-10-01 (Crawled : 00:20) - biospace.com/
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: -1.5%
H: 0.0%
C: 0.0%
treatment positive retina liver trial
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-06-15 (Crawled : 12:00) - biospace.com/
CLSD P | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
| O: 32.42%
H: 20.02%
C: 4.03%
treatment phase 1 positive results trial phase 3 phase 2 axitinib cls-ax dmd injection
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.